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INTRODUCTION 
 
Acute myeloid leukemia myelogenous leukemia (AML) 
is a neoplastic disease of the myeloid hempoietic cells 
described by the accelerated growth of abnormal mye-
loblasts that accumulate in the bone marrow and blood 
and may infiltrate other organs. AML is the most com-
mon acute leukemia affecting adults, and its incidence 
increases with age [1]. Viral oncogenesis has remained 
an area of interest in cancer biology. Viruses have been 
great tutors of cancer biology, helping researchers to 
uncouple many signaling pathways and identifying criti-
cal therapeutic targets. With the advent of advanced 
molecular techniques, more viruses have been attribut-
ed to cause neoplasms in humans [2]. 
The role of infections in carcinogenesis is abundantly 
described. Human cytomegalovirus (HCMV) is a ubiqui-
tous herpes virus that leads to a life-long persistence. 
The frequency of infection ranges from 50% to 100% in 
the general adult population [3]. Human cytomegalovi-
rus causes severe and often fatal disease in immuno-
compromised individuals including recipients of organ 
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transplants and AIDS patients. It routinely reactivates in 
healthy virus carriers, but this is usually controlled by 
the host immune response. Monocytes may be an im-
portant reservoir for latent HCMV; however, the prima-
ry reservoir may be a more primitive cell from the mye-
loid lineage. Reactivation may result from cellular 
differentiation or inflammation [3]. Resistance to apop-
tosis is a mechanism of carcinogenesis and also way for 
resistance to chemotherapy by cancer cells. HCMV in-
fection was reported to protect fibroblasts from apop-
tosis induced by adenovirus E1A protein. Moreover, the 
HCMV IE1-72 and IE2-86 proteins inhibited apoptosis 
induced by the adenovirus E1A and TNF-α and HCMV 
exerts its antiapoptotic effects through IE proteins by 
both p53-independent and p53-dependent mechanism
[4] . 
Few data is available for the incidence of CMV and its 
clinical impact in the prognosis of AML. The aims of the 
present study were to assess prospectively the inci-
dence of active CMV infection in Sudanese patients 
with AML and to describe the impact of CMV in prog-
nosis of AML by the evidence of hematological prog-
nostic markers (TWBC and blast count). 
 
METHODOLOGY  
 
Study design: Analytical case control study 
Ethics approval: The study was approved by the IEC 
and Consents were obtained from the parents/ caregiv-
ers of the subjects and controls after explaining to 
them, in detail, the objectives of the study as well as 
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the method of specimen collection. 
Study locus and period: The patients were attendants 
of clinics and hospital in Khartoum state, Sudan from 
December 2013 to September 2014. 
Sample size: One hundred patients with AML and100 
age and gender healthy controls were studied.  
Inclusion criteria: The diagnosis was confirmed by ex-
amination of both peripheral blood and bone marrow 
examination. All the patients were enrolled in the study 
before receiving the first course of chemotherapy. The 
selection criteria for the patients and controls were the 
lack of recent blood transfusion history and taking any 
medication with mineral supplement. 
Exclusion criteria: Any patients with known history of 
autoimmune diseases or immunosuppression and 
those in medications that affect the immune system 
were excluded.  
Methodology: Five ml of fasting blood sample was col-
lected from the antecubital vein of each of the case and 
control group.  Three ml were taken in an anticoagulat-
ed tube (EDTA) the rest of the sample was taken into 
plain tube.  Samples with signs of hemolysis were dis-
carded. The blood was then allowed to clot and centri-
fuged for 15 minutes at 3000 rpm to extract the serum. 
The serum was aliquoted and stored at -20°C.  
Full blood count  (CBC): Full blood count was per-
formed from EDTA samples within half hour after col-
lection using automated blood cell counter 
(SysmexKX21) to obtain total white cell count. A micro-
scopic examination of peripheral blood film was done 
to get the blast count.  
Immunological Analysis: Serum was test for CMV IgG 
and IgM antibodies by cobas e411 using ECL technology 
(roche diagnostics, Germany). 
Statistical Analysis: Statistical analyses were carried 
out using the SPSS® statistical software package (SPSS 
for Windows version 21.0 SPSS Inc., Chicago, Illinois, 
USA).  
 
RESULTS  
 
Out of the AML patients 85/100 (85.0%) were positive 
for CMV IgG while 18/100 (18%) of them were positive 
for CMV IgM. All the controls 100/100 (100%) were 
negative for CMV IgM and 17/100(17%) were positive 
for CMV IgG. P value in Table 1. 
 
Table 1. The seroprevalence of CMV IgG and IgM anti-
bodies among the case and control groups  
 
Table 2. Comparison of TWBC and blast count be-
tween patients who positive and those who negative 
for CMV (IgG and IgM) antibodies 
 
The total white cell count and blast count were signifi-
cantly higher in AML patients who were positive for 
CMV (IgG or IgM) compared to those who were nega-
tive, P value in Table 2. 
 
DISCUSSION   
 
Human CMV cellular entry activates intracellular signal-
ing pathways such as focal adhesion kinase, mitogen-
activated protein kinase (MAPK), and phosphatidylino-
sitol-3-OH kinase (PI3-K) all of which are known to play 
key roles in cancer progression. In addition, they played 
the role of HCMV gB in cell adhesion and signaling ca-
pabilities. HCMV infection is involved in cancer patho-
gens via modulation of apoptosis, cell migration, and 
angiogenesis. In fact, mixed infections with different 
genotypes of HCMV were detected in healthy and im-
munosuppressed patients, including patients undergo-
ing lung transplant and AIDS patients. In addition, 
mixed genotypes infection was found to be associated 
with increased morbidity and mortality of solid organ 
transplant patients [5]. 
In this study we found that the seroprevlance of CMV 
IgG antibodies was higher in AML patients than in con-
trols indicating an association between AML and CMV 
infections. High incidence of CMV in AML was found by 
Capria and his colloquies and AML patients with CMV 
infection who were not receive antiviral treatment  
were reported to have  more hospital admissions than 
those who received treatment and those with higher 
CMV viremea  had more clinical complications [6]. Early 
treatment of CMV infection in patients with hemato-
logic malignancies resulted in a favorable outcome of 
CMV reactivation [7]. Our results also observed that 
AML patients with CMV infection have poor prognosis 
than those without CMV infection by the evidence of 
hematological prognosis markers considering total 
white cell count and blast count.  
The role of HCMV in cancer etiology was recommended 
for investigation following the development of ad-
vanced and sensitive laboratory techniques that can 
detect virus genomic, protein and secretome products 
in cancer tissues. [3]This being due to facts that reports 
have shown that HCMV-DNA was detected in colorectal 
cancer tissues but not in normal tissues of the colon, 
Group 
CMV IgG CMV IgM 
Positive Negative Positive Negative 
Cases 81 (81%) 19 (19%) 18 (18%) 82 (82%) 
Control 17 (17%) 83(83%) 11 (11%) 100 (100%) 
P value < 0.05 >0.05 
Study 
Group 
CMV IgG CMV IgM 
P value Posi-
tive 
Nega-
tive 
Posi-
tive 
Neg-
ative 
TWBC/µl 
201.0 
± 
78.4 
96.4 ± 
38.8 
187.6 
± 
62.5 
109.8 
± 
43.3 
< 0.05 
Blast 
count/µl 
168.3 
± 
59.8 
88.7 ± 
29.2 
157.5 
± 
55.7 
100.5 
± 
40.2 
< 0.05 
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[8] and in carcinoma tissue of malignant glioma [9] and 
prostate cancer [10]. CMV is reported to have an onco-
genic potential role in breast cancer [11] and to have 
possible causal relationship with mucoepidermoid car-
cinoma [12] . 
 
CONCLUSION 
 
CMV infections may play a role in the carcinogenesis 
and prognosis of AML carcinogenesis. Patients with 
AML should be screened and monitored for CMV as it 
may provide a novel target in cancer treatment. 
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